


Confidently Administer One Platelet for All* with a Transfusion-Ready, Approved Alternative to Bacterial Testing, Gamma Irradiation, and CMV Testing¹

INTERCEPT® Blood System for Platelets Pathogen Reduction System



RISK	Faillogen Reduction (FR)	
Bacterial C	Contamination INTERCEPT PR can be used as	an alternative to bacterial detection. ² Learn More
CMV Trans Transmitte	sfusion- INTERCEPT PR demonstrates i ed Infection ≥4.9 pfu/mL log(10) reduction. ¹	nactivation of CMV in platelets in PAS-3 with



Transfusion-Associated Graft vs. Host Disease (TA-GVHD)



Emerging / **Re-Emerging Pathogens** INTERCEPT PR is FDA approved as an alternative to gamma irradiation for the prevention of TA-GVHD.¹

INTERCEPT PR may eliminate the need for certain donor deferrals/tests and mitigate blood availability risks due to outbreaks.⁴⁻⁷



Intended Use

The INTERCEPT Blood System for Platelets is intended to be used for ex vivo preparation of pathogen-reduced Amicus apheresis platelet components suspended in 65% PAS-3/35% plasma, and Trima apheresis platelet components suspended in 100% plasma in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

Contraindications

*Contraindicated for preparation of platelets intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparati of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emissi bandwidth 4375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. indicated for preparation

Warnings and Precautions

Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and/or container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethlhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

References

- 1. The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation; December 19, 2023. 2. Bacterial FDA Guidance for Industry, Dec 2020.

- ABB Standards 34th edition, 2024.
 Babesiosis FDA Guidance for Industry, May 2019
 Malaria FDA Guidance for Industry, May 2019
 Malaria FDA Guidance for Industry December 2022.
 Allain, J.P., et al., Transfus Med Rev, 2005. 19(2): p. 110-26.
 Rasongles P, et al. Transfusion 2009; 49: 1083-91.

Rx Only. See package inserts (https://intercept-usa.com/resources/?dfg_filter=30) for full prescribing information.



Global Headquarters | 1220 Concord Avenue | Concord, CA US 94520 | 925.288.6000 cerus.com | intercept-usa.com

© 2025 Cerus Corporation. Cerus, INTERCEPT and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00832 v1.0